Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia最新文献

筛选
英文 中文
[In vitro activity of delafloxacin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa in a stage prior to the clinical use of this drug]. [在临床使用该药物之前的阶段,替拉沙星对临床分离的耐碳青霉烯类铜绿假单胞菌的体外活性]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-12-22 DOI: 10.37201/req/080.2023
C García-Rivera, M Navarro, M Parra, A Sánchez Bautista, I Gómez, M P Ventero, J C Rodríguez
{"title":"[In vitro activity of delafloxacin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa in a stage prior to the clinical use of this drug].","authors":"C García-Rivera, M Navarro, M Parra, A Sánchez Bautista, I Gómez, M P Ventero, J C Rodríguez","doi":"10.37201/req/080.2023","DOIUrl":"10.37201/req/080.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"104-105"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138886849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19: On the threshold of the fifth year. The situation in Spain. 2019冠状病毒病:即将进入第五年。西班牙的情况。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-11-27 DOI: 10.37201/req/123.2023
F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, D García de Viedma, E Bouza
{"title":"COVID-19: On the threshold of the fifth year. The situation in Spain.","authors":"F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, J M Molero García, S Moreno Guillén, D García de Viedma, E Bouza","doi":"10.37201/req/123.2023","DOIUrl":"10.37201/req/123.2023","url":null,"abstract":"<p><p>Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising from two Omicron BA.2 sublineages with mutations in the genes encoding the spicule proteins that could increase binding to the ACE2 receptor and be more prone to immune escape. Faced with these, 3 pharmaceutical companies have developed vaccines adapted to the XBB.1.5 sublineage that are already available for administration in our setting with risks that should not be different from those of previous mRNA vaccines and with clearly favorable benefit/risk ratios. They should be applied to patients with potential for poor COVID-19 evolution and to collectives that have a particular relationship of proximity with them. Their application should be understood not only from a perspective of individual convenience but also from that of collective responsibility. The most convenient seems to be a simultaneous immunization of COVID-19 and influenza in our environment. In the therapeutic aspect, there is little to expect right now from antisera, but the already known antiviral drugs are still available and indicated, although their efficacy will have to be reevaluated due to their impact on populations that are mostly immunized and with a better prognosis than in the past. In our opinion, it is necessary to continue to make a reasonable and timely use of masks and other non-pharmacological means of protection.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"17-28"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case report of multiple abscess co-infected with Eggerthella lenta and Desulfovibrio desulfuricans identificated with MALDI-TOF mass spectrometer. MALDI-TOF质谱仪鉴定多脓肿并发大卵杆菌和脱硫弧菌1例。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-12-05 DOI: 10.37201/req/081.2023
D Fernández Vecilla, M P Roche Matheus, M J Urrutikoetxea Gutiérrez, C Aspichueta Vivanco, G Iglesias Hidalgo, I S Pérez Ramos, J L Díaz de Tuesta Del Arco
{"title":"A case report of multiple abscess co-infected with Eggerthella lenta and Desulfovibrio desulfuricans identificated with MALDI-TOF mass spectrometer.","authors":"D Fernández Vecilla, M P Roche Matheus, M J Urrutikoetxea Gutiérrez, C Aspichueta Vivanco, G Iglesias Hidalgo, I S Pérez Ramos, J L Díaz de Tuesta Del Arco","doi":"10.37201/req/081.2023","DOIUrl":"10.37201/req/081.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"106-109"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138483590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy and safety of pediatric flu vaccination: a systematic review]. [儿童流感疫苗接种的有效性和安全性:一项系统综述]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-12-05 DOI: 10.37201/req/101.2023
F M Escandell Rico, L Pérez Fernández
{"title":"[Efficacy and safety of pediatric flu vaccination: a systematic review].","authors":"F M Escandell Rico, L Pérez Fernández","doi":"10.37201/req/101.2023","DOIUrl":"10.37201/req/101.2023","url":null,"abstract":"<p><strong>Objective: </strong>Children are at a higher risk of influenza infection compared to the general population. The World Organization Health and recommendations of the Vaccine Advisory Committee of the Spanish Association of Pediatrics contemplate annual vaccination as the most effective way to prevent the disease. Therefore, the purpose of this review was to update information on efficacy and safety in the anti -shed vaccine in children and adolescents.</p><p><strong>Methods: </strong>A search in four electronic databases (Scopus, Cumulative Index to Nursing and Allied Health Literature, Medline / Pubmed, Google Scholar and Cochrane), as well as a manual search to identify original research published between 2012 and 2022. The guidelines of ANALYSIS (PRISMACR) as a preferred report element for systematic reviews.</p><p><strong>Results: </strong>Seven original research articles were included where two issues of antigripal vaccination were identified in healthy children/adolescents and with pathologies. The efficacy (between approximately 30% and 80%) varied depending on the vaccine used and circulating subtypes. Most adverse reactions were mild intensity, and the most common local adverse event was pain in the injection site.</p><p><strong>Conclusions: </strong>We positively highlight the safety of pediatric flu vaccination in analyzed studies, on the contrary, with respect to the efficacy of flu vaccination, we observe a wide variability of results. There is a clear need to continue conducting efficacy and safety studies in the child.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"43-51"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138483589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diagnostic accuracy of procalcitonin for bacteremia in the emergency department: a systematic review]. [急诊科降钙素原诊断菌血症的准确性:系统综述]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2024-02-01 Epub Date: 2023-12-07 DOI: 10.37201/req/099.2023
A Julián-Jiménez, D Eduardo García, G Merinos-Sánchez, L García de Guadiana-Romualdo, J González Del Castillo
{"title":"[Diagnostic accuracy of procalcitonin for bacteremia in the emergency department: a systematic review].","authors":"A Julián-Jiménez, D Eduardo García, G Merinos-Sánchez, L García de Guadiana-Romualdo, J González Del Castillo","doi":"10.37201/req/099.2023","DOIUrl":"10.37201/req/099.2023","url":null,"abstract":"<p><strong>Objective: </strong>Obtaining blood cultures (HC) is performed in 15% of the patients treated with suspicion of infection in the Hospital Emergency Services (ED) with a variable diagnostic yield (2-20%). The 30-day mortality of patients with bacteremia is two or three times higher than the rest with the same process. Procalcitonin (PCT) is a biomarker that has been used as a tool to help predict bacteremia in HEDs. The main objective of this systematic review is to investigate the diagnostic accuracy of PCT in predicting true bacteraemia in adult patients treated with clinical suspicion of infection in the ED, as well as to identify a specific PCT value as the most relevant from the clinical decision diagnostic point of view that can be recommended for decision making.</p><p><strong>Methods: </strong>A systematic review was performed following the PRISMA guidelines in the PubMed, Web of Science, EMBASE, Lilacs, Cochrane, Epistemonikos, Tripdatabase and ClinicalTrials.gov databases from January 2010 to May 31, 2023 without language restrictions and using a combination of MESH terms: \"Bacteremia/ Bacteraemia/ Blood Stream Infection\", \"Procalcitonin\", \"Emergencies/ Emergency/ Emergency Department\" and \"Adults\". Observational cohort studies and partially an systematic review were included. No meta-analysis techniques were performed, but the results were compared narratively.</p><p><strong>Results: </strong>A total of 1,372 articles were identified, of which 20 that met the inclusion criteria were finally analyzed. The included studies represent a total of 18,120 processed HC with 2,877 bacteraemias (15.88%). Ten studies were rated as high, 9 moderate and 1 low quality. The AUC-COR of all the studies ranges from 0.68 (95% CI: 0.59-0.77) to 0.98 (95% CI: 0.97-0.99). The PCT value >0.5 ng/ml is the most widely used and proposed in up to ten of the works included in this systematic review, whose estimated mean yield is an AUC-COR of 0.833. If only the results of the 6 high-quality studies using a cut-off point (PC) >0.5 ng/mL PCT are taken into account, the estimated mean AUC-COR result is 0.89 with Se of 77.6% and It is 78%.</p><p><strong>Conclusions: </strong>PCT has a considerable diagnostic accuracy of bacteraemia in patients treated in EDs for different infectious processes. The CP>0.5 ng/ml has been positioned as the most suitable for predicting the existence of bacteraemia and can be used to reasonably rule it out.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"29-42"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138500621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of curved Gram-negative rods by MALDI-TOF mass spectrometer in a patient with Fournier ́s gangrene. A bacteremia caused by Desulfovibrio desulfuricans and Escherichia coli. 用MALDI-TOF质谱仪鉴定一例Fournieŕs坏疽患者的弯曲革兰氏阴性杆菌。一种由脱硫弧菌和大肠杆菌引起的菌血症。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2023-12-01 Epub Date: 2023-09-28 DOI: 10.37201/req/026.2023
D Fernández Vecilla, M P Roche Matheus, F E Calvo Muro, G Iglesias Hidalgo, J L Díaz de Tuesta Del Arco
{"title":"Identification of curved Gram-negative rods by MALDI-TOF mass spectrometer in a patient with Fournier ́s gangrene. A bacteremia caused by Desulfovibrio desulfuricans and Escherichia coli.","authors":"D Fernández Vecilla, M P Roche Matheus, F E Calvo Muro, G Iglesias Hidalgo, J L Díaz de Tuesta Del Arco","doi":"10.37201/req/026.2023","DOIUrl":"10.37201/req/026.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"629-631"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines]. [2008年至2022年期间,马德里地区一家二级公立医院引起侵袭性肺炎球菌疾病的血清型的演变,与它们被纳入不同的结合疫苗有关]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2023-12-01 Epub Date: 2023-10-24 DOI: 10.37201/req/034.2023
G Zaragoza Vargas, J Cacho Calvo, R Martínez-Arce, D Molina Arana, B Ramos Blázquez, M Pérez Abeledo, J C Sanz Moreno
{"title":"[Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines].","authors":"G Zaragoza Vargas, J Cacho Calvo, R Martínez-Arce, D Molina Arana, B Ramos Blázquez, M Pérez Abeledo, J C Sanz Moreno","doi":"10.37201/req/034.2023","DOIUrl":"10.37201/req/034.2023","url":null,"abstract":"<p><strong>Objective: </strong>The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022.</p><p><strong>Methods: </strong>313 of S. pneumoniae strains were studied. Serotyping was carried out by latex agglutination (Pneumotest-latex) and the Quellung reaction. In addition, the minimal inhibitory concentration (MIC) was determined against penicillin, erythromycin and levofloxacin by the concentration gradient method (E-test) according the EUCAST breakpoints.</p><p><strong>Results: </strong>The most frequent serotypes throughout the study period were 8, 3, 19A, 1, 11A and 22F corresponding to 46.6% of the isolates. Along 2008-2012 the serotypes 3, 1, 19A, 7F, 6C and 11A represented altogether 53.6% of the isolates. Between 2013 and 2017 the serotypes 3, 8, 12F, 19A, 22F and 19F grouped 51% of the isolates. During 2018-2022 the serotypes 8, 3, 11A, 15A, 4 and 6C included the 55.5% of the cases. In total 5 strains (1.6%) were penicillin resistant, 64 (20.4%) erythromycin resistant and 11 (3.5%) levofloxacin resistant. The MIC50 and MIC90 levels maintained stables along the time.</p><p><strong>Conclusions: </strong>The conjugate vaccines use with different serotype coverage conditioned a decrease of the vaccine-included and an increase of non-covered. Despite these changes, the global antimicrobial susceptibility patterns to erythromycin and levofloxacin maintained relatively stables. The resistance a penicillin was low, not finding this type of resistant strains in the last study period.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"597-603"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49695596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases. 尼马特雷韦/利托那韦和瑞德西韦治疗免疫功能低下的血液系统恶性肿瘤患者的严重急性呼吸系统综合征冠状病毒2型感染的相关性。四个案例系列。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2023-12-01 Epub Date: 2023-10-03 DOI: 10.37201/req/069.2023
A Segura Fábrega, I Pérez Catalán, I Gómez Alfaro, S García Muñoz, C Roig Martí, N Rodríguez Lozano, S Folgado Escudero, M Varea Villanueva, A Gascón Buj, M Torres García, R Reig Valero, R Ferrando Piqueres, J Usó Blasco
{"title":"Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.","authors":"A Segura Fábrega, I Pérez Catalán, I Gómez Alfaro, S García Muñoz, C Roig Martí, N Rodríguez Lozano, S Folgado Escudero, M Varea Villanueva, A Gascón Buj, M Torres García, R Reig Valero, R Ferrando Piqueres, J Usó Blasco","doi":"10.37201/req/069.2023","DOIUrl":"10.37201/req/069.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"655-657"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41180190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Defining new therapeutic scenarios for oritavancin: severe bacteremic Staphylococcus aureus skin and soft tissue infection in a severely immunocompromised oncology patient]. [确定oritavancin的新治疗方案:免疫功能严重受损的肿瘤患者的严重细菌性金黄色葡萄球菌皮肤和软组织感染]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2023-12-01 Epub Date: 2023-10-11 DOI: 10.37201/req/055.2023
J Moreno Izarra, A Brunst, J A Carmona Álvarez, F Aranda, J M Mártir Alario
{"title":"[Defining new therapeutic scenarios for oritavancin: severe bacteremic Staphylococcus aureus skin and soft tissue infection in a severely immunocompromised oncology patient].","authors":"J Moreno Izarra, A Brunst, J A Carmona Álvarez, F Aranda, J M Mártir Alario","doi":"10.37201/req/055.2023","DOIUrl":"10.37201/req/055.2023","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"645-647"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Bacterial coinfection in the critically-ill COVID-19 patient: incidence, impact and need for antimicrobial therapy]. [危重新冠肺炎患者的细菌合并感染:发病率、影响和抗菌治疗的需要]。
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2023-12-01 Epub Date: 2023-09-25 DOI: 10.37201/req/060.2023
P Vidal-Cortés, J Nieto Del Olmo, A I Tizón Varela, E Seoane Fernández, F Eiras Abalde, J Blanco Chapela, L Larrañaga Sigwald, D E Suárez Fernández, P Fernández Ugidos, L Del Río Carbajo
{"title":"[Bacterial coinfection in the critically-ill COVID-19 patient: incidence, impact and need for antimicrobial therapy].","authors":"P Vidal-Cortés, J Nieto Del Olmo, A I Tizón Varela, E Seoane Fernández, F Eiras Abalde, J Blanco Chapela, L Larrañaga Sigwald, D E Suárez Fernández, P Fernández Ugidos, L Del Río Carbajo","doi":"10.37201/req/060.2023","DOIUrl":"10.37201/req/060.2023","url":null,"abstract":"<p><strong>Objective: </strong>To assess the frequency of bacterial coinfection upon ICU admission in SARS-CoV-2 pneumonia patients, its microbiology, and impact on prognosis.The secondary objective was to identify risk factors for coinfection on admission.</p><p><strong>Methods: </strong>Retrospective study, including patients with SARS-CoV-2 pneumonia admitted to the ICU.We defined bacterial coinfection by respiratory symptoms, radiological data, positive and clinically significant microbiological results in samples obtained in the first 48 h of admission and/or a determination of procalcitonin ≥ 0.5 ng/mL in the first 48 h.We evaluated demographic variables, comorbidities, SARS-CoV-2 infection data, severity scores, treatments received, need for respiratory support and outcomes (ICU and hospital mortality).</p><p><strong>Results: </strong>A total of 182 patients were analyzed, 62 (34.1%) with bacterial coinfection.The most frequent microbiology was S. pneumoniae and M. pneumoniae. 96.1% of the patients received antibiotic therapy on admission, 98.9% corticosteroids, 27.5% tocilizumab, and 7.7% remdesivir.85.7% required invasive mechanical ventilation.The SOFA score (OR: 1.315, 95% CI1.116-1.548) and the delay in ICU admission (OR: 0.899, 95% CI 0.831-0.972) were related to the risk of coinfection. Bacterial coinfection increases the risk of death in hospital (OR 2.283; 95% CI 1.011.5.151; p=0.047).</p><p><strong>Conclusions: </strong>Bacterial coinfection is common in COVID patients admitted to the ICU and increases the risk of death. It is not possible to identify with certainty, at the time of admission, which patients do not benefit from antibiotic treatment.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"612-620"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信